Citable filing context
WAT's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | Waters Corporation reported Q2 2026 revenue of $1.645 billion and raised its full-year 2026 financial guidance. |
| May 22, 2026 | other | Waters Corporation reported voting results from its May 21, 2026 annual meeting, approving all submitted proposals. |
| May 5, 2026 | earnings | Waters Corp reported Q1 2026 revenue of $1.267 billion and adjusted EPS of $2.70. |
| Aug 4, 2026 | Guidance: acquired_business_reported_revenue | 3045.00 to 3045.00 |
| Aug 4, 2026 | Guidance: adjusted_eps | 3.95 to 4.05 |
| Aug 4, 2026 | Guidance: adjusted_eps | 14.45 to 14.65 |
| Aug 11, 2026 | mda_quarterly | Waters Corporation’s financial performance for the second quarter and first half of 2026 was significantly impacted by the February 9, 2026, acquisition of the Biosciences and Diagnostic Solutions (BDS) business from Becton, Dickinson and Company. This transaction, structured as a Reverse Morris Trust, contributed $817 million and $1.3 billion in revenue for the second quarter and first half of 2026, respectively. While total net revenues grew 113% and 103% for these periods, the company reported operating losses of $86 million and $134 million. These losses were driven by $253 million in acquisition-related inventory and fixed asset step-up expenses, $372 million in increased purchased intangibles amortization, and $121 million in transaction and integration costs. Legacy business performance remained strong, with organic revenue growth of 7% and 10% for the second quarter and first half, respectively, led by demand for LC and MS instrument systems and chemistry consumables. To manage its expanded capital structure, the company issued $3.5 billion in Senior Notes to repay bridge financing. The company also implemented a 3% workforce reduction to achieve approximately $120 million in annual salary-related savings. Management continues to monitor risks related to global trade policies, including potential tariff impacts and ongoing ERP system implementation. |
| May 12, 2026 | mda_quarterly | Waters Corporation reported a 91% year-over-year revenue increase to $1,267 million for the quarter ended April 4, 2026, primarily driven by the acquisition of Becton, Dickinson and Company’s Biosciences & Diagnostic Solutions (BDS) business. Despite this top-line growth, the company reported an operating loss of $47 million, compared to an operating income of $151 million in the prior-year period. This loss was largely attributable to acquisition-related charges, including $140 million in purchased intangibles amortization, $99 million in inventory and fixed asset fair value step-ups, and $83 million in transaction and integration costs. Excluding the BDS impact, legacy revenue grew 13%, bolstered by demand for liquid chromatography (LC) and mass spectrometry (MS) systems, specifically the Acquity and Xevo TQ-S lines. Geographically, revenue grew significantly in China (68%) and the United States (92%). Total debt reached $5.3 billion following the issuance of $3.5 billion in senior notes to refinance the SpinCo Delayed Draw Term Loan. Key risks include the successful integration of the BDS business, potential supply chain disruptions stemming from evolving tariff policies and recent Supreme Court rulings, and economic volatility in the Chinese market. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
WAT company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.